Related Experiment Videos
DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant
Bertrand Bellier1, Charlotte Dalba, Béatrice Clerc
1Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, CNRS-UMR7087, Université Pierre et Marie Curie, Bat CERVI, Hôpital Pitié-Salpêtrière, 83 Bd de l'Hôpital, 75013 Paris, France.
Vaccine
|February 17, 2006
Summary
New DNA vaccines expressing virus-like particles (VLPs) show strong cellular immune responses. These "plasmo-retroVLPs" protect mice against lethal viral challenge, offering a promising vaccine generation.
Area of Science:
- Vaccinology
- Immunology
- Molecular Biology
Background:
- Virus-like particle (VLP)-based vaccines are highly effective.
- Traditional DNA vaccines expressing non-particulate proteins have shown limited success.
- There is a need to combine VLP immunogenicity with DNA vaccine production ease.
Purpose of the Study:
- To design and evaluate novel DNA vaccines expressing VLPs.
- To assess the immunogenicity and protective efficacy of these engineered DNA vaccines.
Main Methods:
- Constructed DNA vaccines encoding MLV Gag and modified MLV Env proteins designed to form VLPs.
- Included T cell epitopes within the VLP structure.
- Compared efficacy against control plasmids lacking VLP formation capability.
- Tested protection against lethal viral challenge in a mouse model.
Main Results:
- The designed DNA vaccines efficiently induced cellular immune responses.
- These VLP-expressing DNA vaccines conferred protection against a lethal viral challenge in mice.
- Control plasmids unable to form VLPs did not provide protection.
Conclusions:
- Engineered DNA vaccines expressing "plasmo-retroVLPs" are potent immunogens.
- This approach represents a promising second-generation DNA vaccine strategy.
- Combining VLP structure with DNA delivery enhances vaccine efficacy.